Study links GLP-1 drugs, metformin to lower risk of certain cancers [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
The study, which was published Friday on the JAMA Network Open website, showed that patients taking GLP-1 drugs or metformin showed a significantly reduced risk of developing ten cancers associated with obesity than those who took insulin. Researchers noted, however, that GLP-1s didn't appear to lower the risks any more than metformin. Statistically significant risk reductions were observed in GLP-1 users for gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer. The study was based on an analysis of the electronic healthcare records of roughly 1.7M patients with type 2 diabetes who were prescribed a GLP-1 drug, metformin or insulin between 2005 and 2018. The GLP-1 drugs included in the study were first-generation medications such as Novo Nordisk's ( NVO ) Victoza. The study also included Novo's Ozempic, which was approved by the FDA for diabetes i
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk to invest $158 million in insulin plant in Brazil [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk to invest $158 million in insulin plant in Brazil [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list [Yahoo! Finance]Yahoo! Finance
- End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry [BNN Bloomberg (Canada)]BNN Bloomberg
- CNBC Daily Open: October's gravity bringing stocks down [CNBC]CNBC
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 9/30/24 - Form 6-K
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- NVO's page on the SEC website